Radiation Therapy for Dupuytren's Contracture Following Non-Surgical Release

Last updated: November 20, 2024
Sponsor: Dartmouth-Hitchcock Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Radiation therapy

Clinical Study ID

NCT06330545
STUDY02002161
  • Ages > 45
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The goal of this study is to learn about preventing recurrence of Dupuytren's Contracture. The main question it aims to answer are:

• Does targeted radiation therapy decrease recurrence of Dupuytren's contracture after treatment with Collagenase Clostridium Histolyticum?

Participants will undergo:

  • Release of Dupuytren's Contracture after Collagenase Clostridium Histolyticum injection

  • Daily radiation therapy treatment for 5 days followed by 6-8 week rest period and then another course of 5 days of radiation therapy

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 45 or greater with DC

  • Extension deficit >10 degrees

  • Unable to simultaneously place the affected finger and palm flat on a table.

  • Women included in the study will be post-menopausal or using contraception, and apregnancy test will be performed as standard of care.

  • For patients who are having multiple CCH injections, only the first 2 joints ongiven hand will be included

Exclusion

Exclusion Criteria:

  • Unsuccessful non-surgical release (> N/1 disease)

  • They develop an open wound during CCH

  • Breast feeding or pregnancy

  • A chronic muscular, neurologic, or neuromuscular disorder affecting the hands.

  • Less than the age of 45

  • They have previously undergone radiation on the hand in which they plan to get CCHinjections

  • They are pregnant women, impaired adults or prisoners

Study Design

Total Participants: 95
Treatment Group(s): 1
Primary Treatment: Radiation therapy
Phase:
Study Start date:
September 16, 2024
Estimated Completion Date:
April 30, 2032

Study Description

This is a prospective phase II trial where patients diagnosed with late/advanced stage Dupuytren's Contracture (DC) who undergo successful Collagenase Clostridium Histolyticum (CCH) injection and release will receive a standardized regimen of adjuvant radiotherapy (RT). The study will be powered to assess the outcome in patients undergoing the combination of successful release followed by RT. Patients will be monitored for acute and late toxicities while we evaluate disease recurrence defined as a > 20 degree worsening of contracture in the presence of a palpable cord as compared to within 14 days from CCH injection, or the need for medical/surgical intervention to correct the new or worsening contracture.

Connect with a study center

  • Dartmouth Hitchcock

    Lebanon, New Hampshire 03766
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.